- The multi-year strategic partnership will enable GenesisCare to offer patients greater access to leading technology, with a plan to explore further collaborations to improve cancer diagnosis, treatment and cardiovascular care
- The agreement is valued at more than USD 130 million over the next five years, including imaging technologies, digital solutions, clinical education and services
- Together, GenesisCare and GE Healthcare aim to achieve earlier, faster and more confident cancer diagnosis and more precise intervention and individualized treatment, leading to better patient outcomes
Chicago/Sydney – November 9 2020 6 AM CDT GE Healthcare, the leading global provider of advanced medical imaging, and GenesisCare, a leading provider of integrated cancer care globally and cardiovascular care in Australia, today announced a strategic partnership aimed at improving patient outcomes for the two biggest health burdens globally, cancer and heart disease.
GE Healthcare will supply and service the latest CT, MRI, PET/CT, SPECT, digital mammography, and Ultrasound equipment to GenesisCare’s 440+ cancer and cardiovascular disease treatment centers across Australia, the U.S., the U.K., and Spain. The partnership brings together GenesisCare’s leadership in the delivery of cancer and cardiac screening, diagnosis, treatments, and GE Healthcare’s world-class imaging technologies, digital infrastructure, oncology and cardiology solutions, data analytics, and clinical decision support capabilities. GenesisCare recently acquired major U.S. integrated cancer care provider, 21st Century Oncology, increasing access to world-class cancer care for patients across U.S. communities as well as its global network.
Separately, the companies plan to explore further partnership on research activities, with the aim of improving clinical care and outcomes for millions of patients around the world, through technology, education, care pathway development, and theranostics—an innovative and personalized approach that combines molecular imaging and radiotherapy to seek and destroy advanced cancers without damaging healthy tissue.
Cancer is the second-leading cause of death globally after cardiovascular disease (CVD), where cases are predicted to increase by more than 60 percent over the next 20 years. GE Healthcare’s comprehensive diagnostic imaging and monitoring portfolio can be deployed throughout the patient’s cancer or cardiac journey, from initial screening and diagnosis, through therapy guidance facilitating minimally invasive treatment, to monitoring patient progress.
“Together with GenesisCare, we aim to offer patients greater access to leading medical technologies, more precise intervention and individualized treatment leading to a new standard of personalized healthcare,” said GE Healthcare President & CEO, Kieran Murphy. “We hope that combining GenesisCare’s clinical excellence with GE Healthcare’s medical diagnostic innovation and AI capabilities will positively impact millions of cancer and cardiac patients.”
GenesisCare Founder and Global Chief Executive Officer, Mr. Dan Collins, said it was important to continue to increase investment and access for doctors and patients during the current COVID-19 pandemic.
“Cancer and heart disease haven’t stopped during this pandemic, and high-quality imaging and diagnosis will be in greater demand than ever as many people begin to feel more comfortable accessing screening services,” Mr. Collins said.
“Our new global partnership with GE Healthcare will allow for better patient access to state-of-the-art technology and exciting research collaborations that will raise the bar in delivering care for patients of the future. We are delighted to partner with U.S.-headquartered GE Healthcare to help ensure that cancer patients in our more than 290 treatment locations across the U.S. receive rapid access to the latest advancements in oncology treatments.”